These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 21770023)

  • 21. Developmental toxicity testing of biopharmaceuticals in nonhuman primates: previous experience and future directions.
    Martin PL; Weinbauer GF
    Int J Toxicol; 2010 Dec; 29(6):552-68. PubMed ID: 20926830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical evaluation of juvenile toxicity.
    Barrow PC; Barbellion S; Stadler J
    Methods Mol Biol; 2011; 691():17-35. PubMed ID: 20972745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The role of biotechnology in pharmaceutical drug design].
    Gaisser S; Nusser M
    Z Evid Fortbild Qual Gesundhwes; 2010; 104(10):732-7. PubMed ID: 21147436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals.
    Vargas HM; Amouzadeh HR; Engwall MJ
    Expert Opin Drug Saf; 2013 Jan; 12(1):91-102. PubMed ID: 23170873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.
    Ponce R; Abad L; Amaravadi L; Gelzleichter T; Gore E; Green J; Gupta S; Herzyk D; Hurst C; Ivens IA; Kawabata T; Maier C; Mounho B; Rup B; Shankar G; Smith H; Thomas P; Wierda D
    Regul Toxicol Pharmacol; 2009 Jul; 54(2):164-82. PubMed ID: 19345250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving toxicity screening and drug development by using genetically defined strains.
    Festing MF
    Methods Mol Biol; 2010; 602():1-21. PubMed ID: 20012389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonclinical development of biopharmaceuticals.
    Baumann A
    Drug Discov Today; 2009 Dec; 14(23-24):1112-22. PubMed ID: 19853058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals.
    Buckley LA; Chapman K; Burns-Naas LA; Todd MD; Martin PL; Lansita JA
    Int J Toxicol; 2011 Oct; 30(5):583-90. PubMed ID: 22013138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real life juvenile toxicity case studies: the good, the bad and the ugly.
    De Schaepdrijver L; Rouan MC; Raoof A; Bailey GP; De Zwart L; Monbaliu J; Coogan TP; Lammens L; Coussement W
    Reprod Toxicol; 2008 Sep; 26(1):54-5. PubMed ID: 18514481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Developing drugs for pediatric use: a role for juvenile animal studies?
    Baldrick P
    Regul Toxicol Pharmacol; 2004 Jun; 39(3):381-9. PubMed ID: 15135215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pediatric cardiovascular drug development and research: integration of modeling and simulation as one future direction.
    Läer S
    J Cardiovasc Pharmacol; 2011 Sep; 58(3):217-27. PubMed ID: 21654330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Juvenile animal studies for the development of paediatric medicines: a description and conclusions from a European Medicines Agency workshop on juvenile animal testing for nonclinical assessors.
    Silva-Lima B; Due Theilade-Thomsen M; Carleer J; Vidal JM; Tomasi P; Saint-Raymond A
    Birth Defects Res B Dev Reprod Toxicol; 2010 Dec; 89(6):467-73. PubMed ID: 20632393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluations of organ system development in juvenile toxicology testing.
    Robinson K
    Reprod Toxicol; 2008 Sep; 26(1):51-3. PubMed ID: 18595655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical safety evaluation of monoclonal antibodies.
    Lynch CM; Grewal IS
    Handb Exp Pharmacol; 2008; (181):19-44. PubMed ID: 18071940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Juvenile toxicity: are we asking the right questions?
    Downes N
    Toxicol Pathol; 2012 Jul; 40(5):830-7. PubMed ID: 22407308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigative safety science as a competitive advantage for Pharma.
    Moggs J; Moulin P; Pognan F; Brees D; Leonard M; Busch S; Cordier A; Heard DJ; Kammüller M; Merz M; Bouchard P; Chibout SD
    Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1071-82. PubMed ID: 22769724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.